Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise
Rhea-AI Filing Summary
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch exercised stock options to acquire a total of 48,898 shares of common stock on March 12, 2026, at exercise prices of $4.09 and $3.94 per share. These options were granted under the company’s 2018 Stock Option/Stock Issuance Plan and had fully vested based on prior service conditions. Following the transactions, he holds 1,777,725 common shares directly and 25,000 shares indirectly through his spouse. The filing notes he disclaims beneficial ownership of some reported securities beyond his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 48,898 shares
Net Buy
5 txns
Insider
McCulloch Kevin
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 48,894 | $4.09 | $200K |
| Exercise | Stock Option (Right to Buy) | 4 | $3.94 | $15.76 |
| Exercise | Common Stock | 48,894 | $4.09 | $200K |
| Exercise | Common Stock | 4 | $3.94 | $15.76 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 123,769 shares (Direct);
Common Stock — 1,777,725 shares (Direct);
Common Stock — 25,000 shares (Indirect, By Spouse)
Footnotes (3)
- F1. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F2. The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan (the "2018 Plan"). 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.
- F3. The reporting person received the stock options on August 26, 2020 pursuant to an award under the 2018 Plan. 50% of the options vested on the first anniversary of the vesting commencement date, 25% of the options vested on the 18-month anniversary of the vesting commencement date, and the remaining 25% of options vested on the two-year anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Xeris Biopharma (XERS) report for Kevin McCulloch?
Kevin McCulloch exercised stock options to acquire 48,898 Xeris Biopharma common shares. The options were exercised on March 12, 2026 at exercise prices of $4.09 and $3.94 per share, converting previously granted options into directly held common stock.
What were the exercise prices of Kevin McCulloch’s Xeris Biopharma stock options?
McCulloch exercised options at $4.09 and $3.94 per share. These stock options, granted under Xeris Biopharma’s 2018 Stock Option/Stock Issuance Plan, had fully vested according to their service-based vesting schedules before being exercised into common stock.
How were Kevin McCulloch’s exercised Xeris Biopharma options originally granted and vested?
The options were granted under the 2018 Stock Option/Stock Issuance Plan with multi-year vesting. Footnotes state portions vested on the first, 18‑month, and second anniversaries of the vesting commencement date, all subject to continued employment through each vesting milestone.
What does the beneficial ownership disclaimer mean in the Xeris Biopharma Form 4?
The Form 4 states McCulloch disclaims beneficial ownership of some reported securities beyond his pecuniary interest. This standard language clarifies that inclusion of certain shares, such as those held indirectly, is not an admission of full beneficial ownership for regulatory purposes.